Factors or requirements to be considered include (i) presence of Tau seeds and concentrations of Tau seeds in AD/Tauopathy brains, (ii) extracellular localization of Tau seeds and (iii) priming of microglia for subsequent Tau-seed induced inflammasome activation. Here, MAPT is linked to Alzheimer disease.